Pediatric antifungal utilization

Pediatric Infectious Disease Journal

Volumn 27, Issue 12, 2008, Pages 1083-1088

  Prasad, Priya A ^a   Coffin, Susan E ^a,b,c   Leckerman, Kateri H ^a   Walsh, Thomas J ^d   Zaoutis, Theoklis E ^a,b,c,e  

^a Childrens Hospital of Philadelphia   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Center for Pediatric Clinical Effectiveness   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Antifungal therapy; drug utilization; fungal infections; pediatric

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD CARE; COHORT ANALYSIS; DRUG CHOICE; DRUG UTILIZATION; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MYCOSIS; PEDIATRIC HOSPITAL; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; ADOLESCENT; CLINICAL PRACTICE; HOSPITAL; HOSPITAL PATIENT; IMMUNE DEFICIENCY; INCIDENCE; INFANT; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG UTILIZATION; HOSPITALS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFANT; INPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 58149373635     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31817eeee5     Document Type: Article

References (25)

1. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663-678.
2. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36: 621-629.
3. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
4. Zaoutis TE, Cof?n SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J. 2005;24:736-739.
5. Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44:1187-1193.
6. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711-e716.
7. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
8. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J. 2000;19:319-324.
9. Smith PB, Morgan J, Benjamin JD, et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J. 2007;26:197- 200.
10. Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J. 2005;24:358-364.
11. Antachopoulos C, Walsh TJ. New agents for invasive mycoses in children. Curr Opin Pediatr. 2005;17:78-87.
12. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics. 2007; 119:772-784.
13. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis. 2005;18:484-489.
14. Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist Updat. 2005;8:235-245.
15. Feudtner C, Feinstein JA, Satchell M, Zhao H, Kang TI. Shifting place of death among children with complex chronic conditions in the United States, 1989-2003. JAMA. 2007;297:2725-2732.
16. Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD. Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services. Pediatrics. 2001; 107:E99.
17. Averill R, Gold?eld N, Hughes J, et al. What are APR-DRGs? An introduction to the severity of illness and risk of mortality adjustment methodology. 2003.
18. Manzoni P, Stol? I, Pugni L, et al. A multicenter, randomized trial of prophylactic ?uconazole in preterm neonates. N Engl J Med. 2007;356: 2483-2495.
19. Parikh TB, Nanavati RN, Patankar CV, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-1666.
20. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347: 2020-2029.
21. Zaoutis TE, Jafri H, Huang LM, et al. Prospective, multicenter study of caspofungin (CAS) for the treatment of documented fungal infections in pediatric patients. In: Annual Meeting of the Infectious Disease Society of America; 2007; San Diego, CA.
22. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536-4545.
23. Arrieta A, Queiroz-Tellas F, Freire A, et al. Micafungin versus liposo- mal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidaemia. In: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) & 25th International Congress of Chemotherapy (ICC); 2007; Munich, Germany.
24. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
25. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166-2172.